GlassScriptPhysician profile
Lindsey Criss
NPI 1225656952
$15,194.75
in general payments reported to CMS, 2019-2025
46 companies · $4,086 in 2025
The $4,086 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,108 · 2022: $3,643 · 2023: $2,055 · 2024: $3,303 · 2025: $4,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,306 · Travel and Lodging: $2,040 · Education: $98.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,305.98 |
| Travel and Lodging | $2,039.73 |
| Education | $98.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,552.97 | 2024-2025 | Percept PC Brainsense, Intellis Adaptivestim |
| Abbvie INC. | $2,358.61 | 2021-2025 | |
| Boston Scientific Corporation | $1,420.16 | 2022 | |
| Emd Serono, INC. | $1,052.65 | 2021-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $844.65 | 2021-2025 | |
| Biogen, INC. | $830.48 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Pfizer INC. | $475.00 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $435.19 | 2021-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $405.80 | 2022-2025 | Rexulti, Vyepti |
| Ucb, INC. | $382.96 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Amgen INC. | $350.02 | 2021-2025 | Uplizna |
| Kyowa Kirin, INC. | $338.94 | 2021-2025 | Nourianz |
| Eisai INC. | $314.11 | 2024-2025 | |
| Sk Life Science, INC. | $312.44 | 2021-2025 | Xcopri |
| Argenx US, INC. | $285.29 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $276.30 | 2021-2024 | Reyvow, Emgality |
| Genentech USA, INC. | $232.75 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $210.37 | 2021-2022 | |
| Revance Therapeutics, INC. | $207.11 | 2024 | Daxxify |
| Takeda Pharmaceuticals U.S.A., INC. | $189.79 | 2021-2024 | Entyvio |
| Alexion Pharmaceuticals, INC. | $178.36 | 2021-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $175.04 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Ani Pharmaceuticals, INC. | $140.00 | 2022-2024 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $139.96 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $134.91 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $125.96 | 2021 | |
| Jazz Pharmaceuticals INC. | $115.79 | 2022-2024 | |
| Horizon Therapeutics Plc | $95.77 | 2021-2023 | Uplizna |
| Mdd US Operations, LLC | $65.02 | 2024-2025 | Apokyn |
| Tg Therapeutics, INC. | $60.38 | 2023-2024 | |
| Cycle Pharmaceuticals INC | $52.97 | 2025 | Bafiertam, Tascenso Odt |
| Bayer Healthcare Pharmaceuticals INC. | $50.32 | 2021 | |
| Janssen Biotech, INC. | $41.13 | 2025 | Tremfya |
| Axsome Therapeutics, INC. | $40.55 | 2025 | Sunosi |
| Allergan, INC. | $38.55 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $34.87 | 2024-2025 | Rexulti, Nuedexta |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2022 | |
| Vanda Pharmaceuticals INC. | $30.04 | 2025 | Ponvory |
| Acadia Pharmaceuticals INC | $29.36 | 2021-2025 | Nuplazid |
| Acorda Therapeutics, INC | $24.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.71 | 2024 | Dupixent |
| Ardelyx, INC. | $23.50 | 2025 | Ibsrela |
| Ge Healthcare | $18.88 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Csl Behring | $16.50 | 2024 | Hizentra |
| Abbott Laboratories | $14.67 | 2024 | Infinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Criss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.